Common Cabozantinib Adverse Events: Management and Impact on Outcomes and Treatment Duration in Advanced Renal Cell Carcinoma, Hepatocellular Carcinoma, and Radioiodine-Refractory Differentiated Thyroid Cancer
Journal of the Advanced Practitioner in Oncology · 2026-11-09 · 17 (7)
DOI: 10.6004/jadpro.2026.17.7.30 ↗Abstract
Background: Cabozantinib, a tyrosine kinase inhibitor, is a standard-of-care therapy for previously treated advanced renal cell carcinoma, hepatocellular carcinoma, and radioiodine-refractory differentiated thyroid cancer. We evaluated the impact of cabozantinib-associated adverse events (AEs) on treatment outcomes in these populations. Here we report our findings and discuss AE management. Methods: In this post-hoc analysis of three cabozantinib monotherapy pivotal studies (METEOR, CELESTIAL, and COSMIC-311), we compared progression-free survival (PFS) and treatment duration between patients who experienced ≥ 1 any-cause grade ≥ 3 AE and the overall population in the cabozantinib arm of each study. We characterized the most common any-cause AEs leading to dose modification, and advanced practitioner authors provided AE management strategies. Results: Of 923 cabozantinib-treated patients across the studies, the most common grade 3/4 AEs occurring in ≥ 10% of patients in all three studies combined were hypertension (15%), palmar-plantar erythrodysesthesia syndrome (13%), diarrhea (10%), and fatigue (10%). In each trial, median PFS was similar in patients with a grade ≥ 3 AE vs. the respective overall study populations; treatment durations were also similar. Among the four most common any-grade AEs leading to dose modifications, discontinuation rates due to each event were low (< 3%). Advanced practitioner–led AE management strategies included prophylaxis, monitoring, supportive care, and dose modifications. Conclusions: Cabozantinib has a consistent safety profile across indications. With proactive management, patients experiencing grade ≥ 3 AEs had similar PFS outcomes and treatment durations as the overall study populations. Advanced practitioner–led proactive AE management can allow patients to remain on therapy and maximize clinical benefits.
EUVIMED